Diltiazem as a cyclosporine A-sparing agent in heart transplantation: Benefits beyond dose reduction
Open Access
- 14 October 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (41) , e31166
Abstract
Diltiazem (DZ) is widely prescribed in transplant recipients because of its drug-drug interactions with calcineurin inhibitors (CNI). However, these interactions have been primarily investigated in renal transplantation, and data regarding the long-term efficacy and safety of DZ in orthotopic heart transplantation (OHT) are still sparse. Our study aimed to elucidate the extent to which the co-prescription of DZ reduces the dose required to maintain adequate blood levels of cyclosporine A (CsA) and the resulting effect on morbidity and mortality in OHT recipients. We performed a retrospective single-center analysis of OHT recipients on a long-term immunosuppressive regimen based on CsA and mycophenolate mofetil (MMF). The study population consisted of 95 adult OHT recipients with a mean follow-up of 15.8 ± 6.7 years. DZ was co-prescribed in 39 subjects (41.1%) and was associated with a 28.6% reduction of the mean CsA daily dose (P < .001). Patients on DZ had less frequent rejection episodes (P = .002), better renal function (P = .009) and a lower rate of end-stage renal disease (P = .008). Additionally, they developed later cardiac allograft vasculopathy (CAV). We observed no prognostic relevance of DZ co-prescription in univariate and multivariate Cox-regression analyses. In addition to reducing the CsA dose required to maintain adequate blood through levels, DZ may have nephroprotective properties in OHT. The co-administration of DZ may decelerate the development of CAV and reduce the frequency of the rejection episodes. However, the beneficial influence on morbidity has no impact on mortality.Keywords
This publication has 20 references indexed in Scilit:
- International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy—2010The Journal of Heart and Lung Transplantation, 2010
- The effects of diltiazem in renal transplantation patients treated with cyclosporine AJournal of Biomedical Research, 2010
- Long-term follow-up of co-administration of diltiazem and cyclosporine in Chinese kidney transplant recipientsRenal Failure, 2010
- Correlation of C0 and C2 Levels With Cyclosporine Side Effects in Kidney TransplantationTransplantation Proceedings, 2009
- Experience with cyclosporine in heart transplantationTransplantation Proceedings, 2004
- Preservation of renal function during maintenance therapy with cyclosporineTransplantation Proceedings, 2004
- Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipientsNephrology Dialysis Transplantation, 2003
- Diltiazem‐cyclosporin pharmacokinetic interaction — dose–response relationshipBritish Journal of Clinical Pharmacology, 1997
- Antihypertensive effect of amlodipine and lack of interference with cyclosporine metabolism in renal transplant recipients.Hypertension, 1994
- A Preliminary Study of Diltiazem in the Prevention of Coronary Artery Disease in Heart-Transplant RecipientsNew England Journal of Medicine, 1993